Recently, Jiangsu Qyuns Therapeutics Co., Ltd. obtained grant authorization in Australia for its patent application corresponding to the family of “Anti-Human Interleukin-4 Receptor Alpha Monoclonal Antibody and Use Thereof” (Australian title: Monoclonal antibody against human interleukin-4 receptor alpha and use thereof). Previously, this patent family had already received four granted invention patents in China, covering the subjects of “Anti-Human Interleukin-4 Receptor Alpha Monoclonal Antibody and Use Thereof” and “Pharmaceutical Composition for Treating Diseases Associated with IL-4 and/or IL-13 Mediated Signal Transduction.” In Japan, one invention patent was granted under the title “モノクローナル抗体およびその使用 (Monoclonal Antibody Against Human Interleukin4 Receptor Alpha and Its Use)”.

Beijing Caihe Law Firm was engaged by Qyuns Therapeutics to represent the company throughout the entire process of the four Chinese invention patent applications and the PCT international phase, and provided fullprocess advisory services for the related overseas patent family applications—including selecting foreign counsel, preparing documentation, and responding to office actions.

Founded in 2015, Jiangsu Qyuns Therapeutics Co., Ltd. was established by a founding team composed of returnee Ph.D.s and senior experts from China’s biopharmaceutical industry. The company focuses on the research and development of antibody drugs in the fields of autoimmune and allergic diseases, and is dedicated to developing, manufacturing, and commercializing therapeutic antibody drugs that comply with international norms and quality standards.